FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775180619> ?p ?o ?g. }

• W2775180619 endingPage "1847" @default.
• W2775180619 startingPage "1847" @default.
• W2775180619 abstract "Abstract Background: Toll-like receptors (TLRs) are components of the innate immune system that recognize pathogen-associated molecular patterns on bacterial, fungal, or viral pathogens. Intratumoral (IT) injection of unmethylated CG-enriched oligodeoxynucleotide (CpG), a TLR9 agonist, results in local tumor eradication but on its own is not able to induce a systemic anti-tumor immune response. OX40 is a potent costimulatory receptor that can potentiate the action of conventional T cells leading to their proliferation, effector function and survival, but can also inhibit or kill T regulatory cells by ADCC. In previous preclinical studies systemic injection of OX40 agonists increased antitumor immunity and improved survival. Scientific question: Does local injection of both CpG and low doses of an anti-OX40 agonistic antibody trigger a systemic anti-tumor immune response? Results: We implanted the A20 lymphoma tumor bilaterally on opposite sides of the abdomen. After tumors were established we administered microgram quantities of CpG and anti-OX40 antibody into the tumor on one side and monitored both the injected and the uninjected tumor sites. This treatment resulted in both a local and an abscopal effect on the contralateral, untreated tumor. In addition, the animals were protected from a second challenge with A20 cells. This anti-tumor effect was T cell dependent, since depletion of either CD4+ or CD8+ T cells abrogated the therapeutic effect. There was no evidence of toxicity or autoimmunity in the treated animals. To examine the potential of this maneuver to treat spontaneous, non-transplanted cancers we chose the mouse mammary tumor model- FVB/N-Tg(MMTV-PyVT)634Mul/J. These animals all develop invasive breast cancer tumors in all of their mammary glands by 12 weeks of age. Injections of CpG and anti-OX40 antibody into the first arising tumor not only prevented its growth but significantly reduced the incidence and outgrowth of subsequent tumors at un-injected susceptible mammary glands and reduced the number of lung metastases. Significance: TLR9 agonists and anti-OX40 antibodies are currently under clinical development for cancer treatment. We show here that combining anti-OX40 antibody with a TLR9 agonist at a single established tumor is sufficient to trigger a systemic anti-tumor response able to eradicate tumor at distant sites in both transplantable and spontaneously occurring oncogene-driven murine tumors. This anti-tumor effect was long lasting, specific and required T cells. Impact: Our current results suggest that CpG and anti-OX40 are sufficient to induce fully protective and curative anti-tumor immune responses, even in spontaneously arising cancer. Anti-OX40 and CpG are both currently in phase-I clinical trials as single agents. Our results provide the rationale for testing these agents clinically in combination as described here, injected locally in low doses in order to induce therapeutic anti-lymphoma immunity. Disclosures Levy: Kite Pharma: Consultancy; Five Prime Therapeutics: Consultancy; Innate Pharma: Consultancy; Beigene: Consultancy; Corvus: Consultancy; Dynavax: Research Funding; Pharmacyclics: Research Funding." @default.
• W2775180619 created "2017-12-22" @default.
• W2775180619 creator A5003844260 @default.
• W2775180619 creator A5072352701 @default.
• W2775180619 creator A5083342021 @default.
• W2775180619 date "2016-12-02" @default.
• W2775180619 modified "2023-09-27" @default.
• W2775180619 title "In Situ Vaccination with a TLR9 Agonist and Anti-OX40 Antibody Leads to Tumor Regression and Induces Abscopal Responses in Murine Lymphoma" @default.
• W2775180619 doi "https://doi.org/10.1182/blood.v128.22.1847.1847" @default.
• W2775180619 hasPublicationYear "2016" @default.
• W2775180619 type Work @default.
• W2775180619 sameAs 2775180619 @default.
• W2775180619 citedByCount "2" @default.
• W2775180619 countsByYear W27751806192019 @default.
• W2775180619 countsByYear W27751806192020 @default.
• W2775180619 crossrefType "journal-article" @default.
• W2775180619 hasAuthorship W2775180619A5003844260 @default.
• W2775180619 hasAuthorship W2775180619A5072352701 @default.
• W2775180619 hasAuthorship W2775180619A5083342021 @default.
• W2775180619 hasConcept C104317684 @default.
• W2775180619 hasConcept C136449434 @default.
• W2775180619 hasConcept C150194340 @default.
• W2775180619 hasConcept C159654299 @default.
• W2775180619 hasConcept C167672396 @default.
• W2775180619 hasConcept C190727270 @default.
• W2775180619 hasConcept C193419808 @default.
• W2775180619 hasConcept C203014093 @default.
• W2775180619 hasConcept C2777701055 @default.
• W2775180619 hasConcept C2779138994 @default.
• W2775180619 hasConcept C2781274730 @default.
• W2775180619 hasConcept C502942594 @default.
• W2775180619 hasConcept C55493867 @default.
• W2775180619 hasConcept C71924100 @default.
• W2775180619 hasConcept C86803240 @default.
• W2775180619 hasConcept C8891405 @default.
• W2775180619 hasConceptScore W2775180619C104317684 @default.
• W2775180619 hasConceptScore W2775180619C136449434 @default.
• W2775180619 hasConceptScore W2775180619C150194340 @default.
• W2775180619 hasConceptScore W2775180619C159654299 @default.
• W2775180619 hasConceptScore W2775180619C167672396 @default.
• W2775180619 hasConceptScore W2775180619C190727270 @default.
• W2775180619 hasConceptScore W2775180619C193419808 @default.
• W2775180619 hasConceptScore W2775180619C203014093 @default.
• W2775180619 hasConceptScore W2775180619C2777701055 @default.
• W2775180619 hasConceptScore W2775180619C2779138994 @default.
• W2775180619 hasConceptScore W2775180619C2781274730 @default.
• W2775180619 hasConceptScore W2775180619C502942594 @default.
• W2775180619 hasConceptScore W2775180619C55493867 @default.
• W2775180619 hasConceptScore W2775180619C71924100 @default.
• W2775180619 hasConceptScore W2775180619C86803240 @default.
• W2775180619 hasConceptScore W2775180619C8891405 @default.
• W2775180619 hasIssue "22" @default.
• W2775180619 hasLocation W27751806191 @default.
• W2775180619 hasOpenAccess W2775180619 @default.
• W2775180619 hasPrimaryLocation W27751806191 @default.
• W2775180619 hasRelatedWork W1992979622 @default.
• W2775180619 hasRelatedWork W2029990186 @default.
• W2775180619 hasRelatedWork W2169035834 @default.
• W2775180619 hasRelatedWork W2181883721 @default.
• W2775180619 hasRelatedWork W2326475792 @default.
• W2775180619 hasRelatedWork W2496937664 @default.
• W2775180619 hasRelatedWork W2557679868 @default.
• W2775180619 hasRelatedWork W2560625304 @default.
• W2775180619 hasRelatedWork W2584239571 @default.
• W2775180619 hasRelatedWork W2586494237 @default.
• W2775180619 hasRelatedWork W2627028493 @default.
• W2775180619 hasRelatedWork W2740744394 @default.
• W2775180619 hasRelatedWork W2741492164 @default.
• W2775180619 hasRelatedWork W2914950615 @default.
• W2775180619 hasRelatedWork W2919692814 @default.
• W2775180619 hasRelatedWork W2944788820 @default.
• W2775180619 hasRelatedWork W2980089295 @default.
• W2775180619 hasRelatedWork W3020709155 @default.
• W2775180619 hasRelatedWork W3168823718 @default.
• W2775180619 hasRelatedWork W3199385148 @default.
• W2775180619 hasVolume "128" @default.
• W2775180619 isParatext "false" @default.
• W2775180619 isRetracted "false" @default.
• W2775180619 magId "2775180619" @default.
• W2775180619 workType "article" @default.